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Abstract: Modaﬁ  nil, a wakefulness-promoting agent unrelated to classical sympathomimetic 
stimulants, has been studied in a total of 933 children and adolescents as a treatment for attention-
deﬁ  cit/hyperactivity disorder (ADHD). Several studies, including three double-blind, placebo-
controlled studies with intent-to-treat analyses, have demonstrated the efﬁ  cacy of modaﬁ  nil 
ﬁ  lm-coated tablets in reducing symptoms of ADHD and associated problem behaviors in children 
and adolescents. Modaﬁ  nil is generally well tolerated, with adverse events (such as insomnia, 
headache, loss of appetite, weight loss, and gastrointestinal discomfort) that are generally mild 
to moderate, rarely leading to medication discontinuation. To minimize treatment-emergent 
side effects, titration to the target dose of 355–425 mg once a day should take place over 2–3 
weeks. Due to reports of skin rash (including one case of possible erythema multiforme/Stevens 
Johnson Syndrome during pivotal studies), additional studies have been requested to better 
evaluate the risks of developing severe cutaneous adverse reactions. 
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Pharmacological management of children and adolescents with attention-deﬁ  cit/hyper-
activity disorder (ADHD) often results in improvements in symptoms of inattention 
(distractibility, forgetfulness, inability to concentrate), in symptoms of hyperactivity-
impulsivity (restlessness, ﬁ  dgetiness, impulsive responses), and in overall quality of 
life (Brown et al 2005; King et al 2006). Sympathomimetic stimulants are the most 
common treatment for ADHD (Brown et al 2005; Arnsten 2006), but a sizable minority 
of children and adolescents with ADHD do not respond adequately to these medications 
or have intolerable side-effects (Brown et al 2005; King et al 2006). Thus, additional 
treatments for ADHD are sought. Modaﬁ  nil has been evaluated as a potentially effective 
medication in reducing problematic symptoms of ADHD. 
Molecular and biologic characteristics of modaﬁ  nil
Modaﬁ  nil (Provigil®, Cephalon, Inc., Frazer, PA, USA) is a wakefulness-promoting 
medication that is structurally different from the classical stimulants (methylphenidate, 
amphetamines, and pemoline; see Figure 1). Besides being structurally unique, the 
neurophysiological properties of modaﬁ  nil are also unique in comparison with sym-
pathomimetic stimulants (Lin et al 1992, 1996; Simon et al 1995; Shelton et al 1995; 
Ferraro et al 1997). Besides a low afﬁ  nity for the dopamine reuptake carrier site with 
only a slight increase in extracellular dopamine (Mignot et al 1994), modaﬁ  nil does not 
bind to nor does it have signiﬁ  cant agonist or antagonist activity at any of the known 
CNS neuronal catecholamine, cholinergic or amino acid/neuropeptide receptors or 
transporters (Cephalon 2006). In contrast to the sympathomimetic stimulants, physi-
ological effects of modaﬁ  nil are not a direct result of dopaminergic or noradrenergic Neuropsychiatric Disease and Treatment 2007:3(3) 294
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activity (Akaoka et al 1991; DeSereville et al 1994; Ferraro 
et al 1997).
Whereas methylphenidate and amphetamine stimulants 
have a wide distribution of direct neuronal activity throughout 
the cortex, basal ganglia, and nucleus accumbens, preclini-
cal studies of modaﬁ  nil demonstrate more limited binding, 
primarily in the hypothalamus (Lin et al 1996). Increased neu-
ronal activity (as evidenced by increased c-fos activity) was 
found primarily in orexin neurons of the tuberomammilary 
nucleus, even with administration of low doses of modaﬁ  nil 
(Scammell et al 2000). This area of the brain is implicated 
in regulating physiologic wakefulness (Chemelli et al 1999; 
Scammell et al 2000). Evidence also exists for inhibition of the 
sleep-promoting neurons of the ventrolateral preoptic nucleus 
after modaﬁ  nil adminstration (Gallopin et al 2004).
Notable in these preclinical studies is the lack of sig-
niﬁ  cant activity in the nucleus accumbens (Lin et al 1996; 
Ferraro et al 1997; Scammell et al 2000), the brain’s reward/
reinforcement center (which mediates most of the addictive 
properties of drugs such as cocaine, opioids, and stimulants). 
Several studies have conﬁ  rmed the low abuse potential 
of modaﬁ  nil (Deroche-Gamonet et al 2002; Myrick et al 
2004), with less cocaine-like discriminative-stimulus effects 
and self-reported stimulant effects than methylphenidate 
or amphetamines (Gold 1996; Jasinski 2000; Jasinski and 
Lovacevic-Ristanovic 2000; Rush et al 2002a, b).
Although approved by the US Food and Drug Adminis-
tration for improving wakefulness in adults with excessive 
sleepiness associated with narcolepsy, obstructive sleep 
apnea/hypopnea, and shift work sleep disorder 16 years of 
age and older (Cephalon 2004), its mechanism of action 
in humans is not fully understood. After administration of 
modaﬁ  nil, functional MRI (fMRI) has shown activation of 
the anterior cingulate cortex during a task of working memory 
(Spence et al 2005), and an activation of other cortical areas 
(particularly in individuals with low initial activation lev-
els; Ellis et al 1999). This is very signiﬁ  cant, considering 
that the anterior cingulate cortex was notably deﬁ  cient in 
fMRI activity in individuals with ADHD during a working 
memory task (Bush et al 1999). A likely hypothesis regarding 
modaﬁ  nil’s physiologic effects is that modaﬁ  nil indirectly 
activates the cerebral cortex (including areas implicated in 
ADHD pathology) via ascending arousal pathways arising 
from the hypothalamus (eg, the tuberomammillary nucleus; 
see Figure 2).
Modaﬁ  nil is well absorbed from the gastrointestinal tract, 
but bioavailability cannot he determined since low water 
solubility makes i.v. administration unfeasible (Cephalon 
2004, 2006). Peak levels are seen at 2–4 hours after oral 
administration, but about 1 hour later if administered with food 
(Cephalon 2004, 2006). Metabolized by several cytochrome 























Figure 1 Chemical structures of modaﬁ  nil, methylphenidate, amphetamine, and pemoline.Neuropsychiatric Disease and Treatment 2007:3(3) 295
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CYP1A2, CYP2B6, CYP3A4, and is a mild inhibitor of 
CYP2C19 (Cephalon 2004). Therefore, interactions with 
medicines may be seen with diazepam, propranolol, phenytoin, 
S-mephenytoin, and tricyclic or some SSRI antidepressants (in 
poor metabolizers of CYP2D6), whereas decreased efﬁ  cacy 
of added medicines may be seen with cyclosporine and birth 
control hormones (Cephalon 2004). Strong CYP3A4 inducers 
(such as carbamazepine, phenobarbital, and rifampin) or 
inhibitors (such as ketoconazole or itraconazole) may slightly 
alter modaﬁ  nil blood levels (Cephalon 2004).
Half-life in adults is approximately 15 hours, but is 
shorter for children and adolescents. For children 6–7 years of 
age, the half-life is about 7 hours (Cephalon 2006). The half-
life gradually lengthens until 9–11 years, when a pronounced 
shift is seen approaching adult levels (Cephalon 2006).
Efﬁ  cacy in children and adolescents 
with ADHD
After two investigator-initiated independent studies sug-
gested possible efﬁ  cacy of modaﬁ  nil in children with ADHD 
(Rugino and Copley 2001; Rugino and Samsock 2003), a 
phase 2 study of 248 children and adolescents aged 6–13 
years was completed to determine if divided doses were 
effective, tolerated, and necessary to treat children with 
ADHD. The subjects who received 300 mg once per day 
showed consistently greater improvement in home and 
school ADHD Rating Scale IV (ADHD-RS-IV; DePaul G, 
et al 1998) total scores as well as in Conners Parent Rating 
Scales (CPRS; Connors 1997) ADHD DSM-IV total scores, 
whereas subjects who received 300 mg per day in divided 
doses showed less consistent improvements in ADHD symp-
toms (Biederman et al 2006b). The pharmacokinetic data 
from this and other phase 2 studies allowed for computer 
modeling of the exposure – response relationship. Using a 
target range for the area under the plasma drug concentration 
versus time curve (AUC0-24) of 150 μg × hours/mL, doses 
of 340 mg/day were found to be the most appropriate target 
dose if the child’s weight was <30 kg and 425 mg/day if the 
child’s weight was ≥30 kg (Cephalon 2006). 
Three phase 3 studies involving a total of 638 children 
and adolescents with ADHD aged 6 to 17 years conﬁ  rmed 
the clinical efﬁ  cacy of 85 mg modaﬁ  nil ﬁ  lm-coated com-
pressed tablets when administered as once-daily doses of 
up to 340–425 mg over 7–9 weeks (Biederman et al 2005; 
Swanson et al 2006; Greenhill et al 2006). For each of the 
studies, the diagnosis of ADHD was conﬁ  rmed with the Diag-




















Figure 2 Indirect activation of the cerebral cortex by modaﬁ  nil action on the tuberomammillary nucleus. Adapted from Swanson et al (1998). 
Abbreviations: SN, suprachiasmatic nucleus; TMN, tuberomammilary nucleus; VTA, ventral tegmental area.Neuropsychiatric Disease and Treatment 2007:3(3) 296
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IV), and severity of illness was conﬁ  rmed with scores ≥1.5 
standard deviations above the age- and gender-based mean 
on the ADHD-RS-IV: School Version. Mental impairment, 
uncontrolled psychological comorbidity, and signiﬁ  cant 
medical problems excluded subjects from these studies. As 
is observed in most ADHD studies involving children and 
adolescents, most of the subjects of these studies (Biederman 
et al 2005; Swanson et al 2006; Greenhill et al 2006) had 
ADHD, Combined Type (59%–71%), were male (2.4–2.7:1), 
and were moderately to markedly ill (82%–91%).
Two ﬂ  exible-dose studies (Biederman et al 2005; Green-
hill et al 2006) and one ﬁ  xed-dose study (Swanson et al 2006) 
documented efﬁ  cacy of a ﬁ  lm-coated compressed tablet 
formulation of modaﬁ  nil using an intent-to-treat analysis 
with 2:1 ratio of treatment: control and with the endpoint 
deﬁ  ned as the last obtained value carried forward. In the 
ﬂ  exible-dose studies, the mean and modal stable doses were 
361–369 mg/day and 425 mg/day (range 170–425 mg once 
daily every morning), whereas the ﬁ  nal administered dose 
in the ﬁ  xed-dose study was 340 mg for children <30 kg and 
425 mg for subjects ≥30 kg. For all three studies and for 
pooled data (Cephalon 2006), ADHD-RS-IV scores dem-
onstrated improvements consistently in favor of modaﬁ  nil 
for the primary outcome measure (the School Version of the 
ADHD-RS-IV, see Figures 3a, b, c), the Home Version of 
the ADHD-RS-IV, as well as for the inattentive and hyperac-
tive-impulsive subscale scores of each version. There were no 
effects of race, sex, weight, ADHD subtype, or comorbidity 
in the improvements seen with modaﬁ  nil treatment (Cephalon 
2006). More improvement was seen in patients less than 12 
years of age compared with older patients. Modaﬁ  nil was 
efﬁ  cacious in treating both stimulant-naïve patients and those 
who had received prior stimulant therapy. ADHD-RS-IV: 
School Version total scores showed a reduction of ≥30% in 
64%–69% of modaﬁ  nil-treated subjects (as compared with 
35%-39% of controls, p < 0.0001) and a reduction of ≥50% 
for 44%–48% of modaﬁ  nil-treated subjects as compared 
with 19%–20% of controls, p < 0.001) for each of the studies 
(Biederman et al 2005; Swanson et al 2006; Cephalon 2006; 
Greenhill et al 2006). Using the ADHD-RS-IV: School Ver-
sion total score data and Cohen’s calculations, the overall 
pooled effect size was 0.69; this corresponds to a medium-
to-large effect (Cohen 1988). The greatest effect was seen in 
drug-naïve subjects, in whom the calculated effect size was 
1.08 (treatment n = 221 and control n = 102).
For all three of these double-blind, placebo-controlled 
studies (Cephalon 2006), the ADHD Rating Scale-IV scores 
continued to improve while subjects were followed week-
to-week (see Figure 3). Nonetheless, improvements were 
often seen at the ﬁ  rst follow-up visit (week 1 of treatment; 
Swanson et al 2006; Greenhill et al 2006).
Figure 4 outlines the Clinical Global Impression of 
Change ratings from these studies (Cephalon 2006), deﬁ  n-
ing a clinical response as “very much improved” or “much 
improved.” Patients treated with modaﬁ  nil showed greater 
improvement in overall clinical condition than those receiv-
ing placebo at all study visits and for the last observation 
carried forward (46% vs 18%). Based on the pooled data 
(Cephalon 2006), the number needed to treat was 3.5 (95% 
conﬁ  dence interval = 2.8–4.7).
Figure 3a ADHD Rating Scale total scores as a function of time in a ﬂ  exible-dose study of efﬁ  cacy of modaﬁ  nil for children and adolescents with attention-deﬁ  cit/hy-
peractivity disorder (n = 194). *p values <0.05; endpoint represents the last obtained value carried forward Reproduced from Cephalon, Inc. 2006. Modaﬁ  nil (CEP-1538) 
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Using the Social Skills Rating Scale (SSRS; Gresham 
and Elliot 1990), statistically significant improvements 
favoring modaﬁ  nil treatment were seen at endpoint for the 
externalizing subscale score, the internalizing subscale score, 
and the hyperactivity subscale score as well as for the prob-
lem behaviors total score (Biederman et al 2005; Swanson 
et al 2006; Cephalon 2006; Greenhill et al 2006). Along 
with reductions in problem behaviors, the SSRS analysis 
suggested that modaﬁ  nil resulted in improvements in the 
subscale scores for cooperation, assertion, responsibility, 
and self-control (Biederman et al 2005; Swanson et al 2006; 
Cephalon 2006; Greenhill et al 2006).
Safety and tolerability
The 7-week ﬁ  xed-dose study was followed by an abrupt 
double-blind, placebo-controlled 2-week withdrawal from 
treatment (Swanson et al 2006). No withdrawal symptoms, 
rebound exacerbation of ADHD symptoms, or rebound 
hypersomnolence was reported from the subjects who were 
abruptly withdrawn from modaﬁ  nil. 
Figure 3b ADHD Rating Scale total scores as a function of time for a ﬂ  exible-dose study of modaﬁ  nil efﬁ  cacy for children and adolescents with attention-deﬁ  cit/hyperac-
tivity disorder (n = 244). *p values <0.05; endpoint represents the last obtained value carried forward.Reproduced from: Cephalon, Inc. 2006. Modaﬁ  nil (CEP-1538) tablets 
Supplemental NDA 20-717/S-019 ADHD indication. Brieﬁ  ng document for Psychopharmacologic Drugs Advisory Committee Meeting March 26, 2006. Frazer, PA: Cephalon, 
Inc.
Figure 3c ADHD Rating Scale total scores as a function of time for a ﬁ  xed-dose study of efﬁ  cacy of modaﬁ  nil for children and adolescents with attention-deﬁ  cit/hy-
peractivity disorder (n = 183). *p values <0.05; endpoint represents the last obtained value carried forward Reproduced from Cephalon, Inc. 2006. Modaﬁ  nil (CEP-1538) 
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During the three cited double-blind, placebo-controlled 
studies (Biederman et al 2005; Swanson et al 2006; Greenhill 
et al 2006), 420 subjects received modaﬁ  nil treatment; 
55% of subjects had at least one treatment-related adverse 
event, as compared with 29% of control patients (Cephalon 
2006). Since the ﬂ  exible-dose studies (Biederman et al 
2005; Greenhill et al 2006) proceeded with a slower upward 
titration (over the course of 3 weeks) than the ﬁ  xed-dose 
study (over the course of 7–9 days; Swanson 2006), and 
since the ﬂ  exible-dose studies halted upward titration when 
adequate efﬁ  cacy was determined, the frequency of adverse 
events was lower in the ﬂ  exible dose studies than in the ﬁ  xed 
dose study. In each of the ﬂ  exible dose studies (Biederman 
et al 2005; Greenhill et al 2006), modaﬁ  nil-treated patients 
did not discontinue the study because of an adverse event at 
a rate higher than placebo, whereas more modaﬁ  nil-treated 
subjects discontinued the study for an adverse event than 
control subjects (10% vs 0%) in the ﬁ  xed dose study (Swanson 
et al 2006). 
Table 1 describes the adverse events that occurred in at 
least 5% of the modaﬁ  nil-treated patients and that occurred 
more frequently than in the control group (Cephalon 2006). 
When analyzing the pooled data (Cephalon 2006), Seventy-
ﬁ  ve percent of the adverse events developed within the 
ﬁ  rst 2 weeks of treatment (during upward dose titration). 
Insomnia was the most frequent adverse event (Biederman 
et al 2005; Swanson et al 2006; Cephalon 2006; Greenhill 
et al 2006), was described as severe in 9 cases and resulted in 
discontinuation of modaﬁ  nil in 5 cases. Insomnia, headache, 
and gastrointestinal concerns (loss of appetite or abdominal 
pain) were the most common adverse events that resulted in 
discontinuation, but fever and nervousness were also rare 
0











Figure 4a Percentage responders as a function of time for a ﬂ  exible-dose study of efﬁ  cacy of modaﬁ  nil for children and adolescents with attention-deﬁ  cit/hyperactivity 
disorder (n = 194). Response is deﬁ  ned as having a Clinical Global Impressions of Change score of 1 (“very much improved”) or 2 (“much improved”). 
*p values <0.05; EP = endpoint, which represents the last obtained value carried forward. Reproduced from Cephalon, Inc. 2006. Modaﬁ  nil (CEP-1538) tablets Supplemental 
NDA 20-717/S-019 ADHD indication. Brieﬁ  ng document for Psychopharmacologic Drugs Advisory Committee Meeting March 26, 2006. Frazer, PA: Cephalon, Inc.
Figure 4b Percentage responders as a function of time for a ﬂ  exible-dose study of efﬁ  cacy of modaﬁ  nil for children and adolescents with attention-deﬁ  cit/hyperactivity 
disorder (n = 244). Response is deﬁ  ned as having a Clinical Global Impressions of Change score of 1 (“very much improved”) or 2 (“much improved”). *p values <0.05; EP = 
endpoint, which represents the last obtained value carried forward.Reproduced from Cephalon, Inc. 2006. Modaﬁ  nil (CEP-1538) tablets Supplemental NDA 20-717/S-019 
ADHD indication. Brieﬁ  ng document for Psychopharmacologic Drugs Advisory Committee Meeting March 26, 2006. Frazer, PA: Cephalon, Inc.
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causes for discontinuation (Biederman et al 2005; Swanson 
et al 2006; Cephalon 2006; Greenhill et al 2006).
Anorexia/decreased appetite was reported in 16% 
of subjects (Biederman et al 2005; Swanson et al 2006; 
Cephalon 2006; Greenhill et al 2006) and was associated 
with a 0.7 kg decrease of body weight during the 7–9 weeks 
of treatment of the three phase 3 studies (compared with 
the control group that gained 1 kg during the same time 
period). However, during a 12 month open-label extension 
study (Cephalon 2006) that followed the phase 3 studies, the 
weight z scores (compared with the norms established by the 
National Center for Health Statistics; Kucsmanski et al 2000) 
indicated that the subjects were heavier than average at base-
line, and the z scores stabilized after 3 months of treatment. 
On the other hand, height z scores did not appear to decline 
over the 12-month extension period (Cephalon 2006).
No signiﬁ  cant changes in resting heart rate, resting blood 
pressure, or electrocardiographic ﬁ  ndings were found with 
administration of modaﬁ  nil in doses from 85 mg to 425 mg 
(Biederman et al 2005; Swanson et al 2006; Cephalon 2006; 
Greenhill et al 2006).
Among all children and adolescents who were admin-
istered modaﬁ  nil as a part of clinical studies for ADHD 
(n = 933; Cephalon 2006), a total of 18 serious adverse 
events were described. Of these, only two were reported as 
“probably” or “possibly” related to modaﬁ  nil: a maculo-
papular/morbiliform rash and a case of possible erythema 
multiforme/Stevens-Johnson Syndrome (Biederman et al 
2005). All of these skin lesions resolved without sequelae 
(Cephalon 2006). Six additional subjects (n = 933) discontin-
ued modaﬁ  nil treatment for concerns of rash, with resolution 
Cephalon 2006). Post-marketing experience was reviewed in 
light of these skin concerns. Five reports of severe cutaneous 
adverse reactions have been made since 1999, during which 
time approximately 673,000 adults have taken modaﬁ  nil 
worldwide (Cephalon 2006). Further studies evaluating the 
relationship between the skin rashes and modaﬁ  nil/modaﬁ  nil 
sulfone have been requested by the United States Food and 
Drug Administration.
Psychiatric adverse events, such as aggression, suicidal 
ideation, and psychosis/mania were recently reported to be 
consequences of the various medications used to treat ADHD 
(Gelpirin 2006). In double-blind and open-label studies for 
children and adolescents with ADHD (n = 933, Cephalon 
2006), aggression was reported for 1.4 to 1.8% of subjects 
taking modaﬁ  nil. A total of 5 subjects reported symptoms 
of psychosis/mania (one of whom required hospitalization) 
and 5 reported transient suicidal ideation (most of whom 
had resolution despite continuing modaﬁ  nil treatment). As 
observed with other ADHD treatments (Celpirin 2006), 
Figure 4c Percentage responders as a function of time for a ﬁ  xed-dose study of efﬁ  cacy of modaﬁ  nil for children and adolescents with attention-deﬁ  cit/hyperactivity 
disorder (n = 183). Response is deﬁ  ned as having a Clinical Global Impressions of Change score of 1 (“very much improved”) or 2 (“much improved”). *p values <0.05; EP = 
endpoint, which represents the last obtained value carried forward. Reproduced from Cephalon, Inc. 2006. Modaﬁ  nil (CEP-1538) tablets Supplemental NDA 20-717/S-019 
ADHD indication. Brieﬁ  ng document for Psychopharmacologic Drugs Advisory Committee Meeting March 26, 2006. Frazer, PA: Cephalon, Inc.
Table 1 Adverse events occurring in at least 5% of modaﬁ  nil-
treated subjects which occurred more frequently than in the 
control group during the three phase 3 studies (pooled data) 
  Number (%)   of subjects 
Adverse event   Modaﬁ  nil (n = 420)  Placebo (n = 213)
Insomnia   115 (27)  8 (4)
Headache   82 (20)  27 (13)
Anorexia/appetite 
decrease  67 (16)  6 (3)
Abdominal pain   40 (10)  17 (8)
Fever   21 (5)  7 (3)
Nervousness   19 (5)  9 (4)
Reproduced from Cephalon, Inc. Modaﬁ  nil (CEP-1538) tablets Supplemental NDA 
20-717/S-019 ADHD Indication. Brieﬁ  ng document for Psychopharmacologic Drugs 
Advisory Committee Meeting March 23, 2006. Frazer, PA: Cephalon, Inc. 
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many of these subjects had no prior remarkable history of 
similar events. 
Conclusion
Modaﬁ  nil, when titrated to effect with a target dose of 340 
mg (body weight <30 kg) or 425 mg (body weight ≥30 kg) 
over the course of 2–3 weeks, is effective in managing the 
symptoms of and the problem behaviors associated with 
attention-deﬁ  cit/hyperactivity disorder in children and ado-
lescents. It is generally well tolerated, with adverse events 
(such as insomnia, headache, loss of appetite, weight loss, 
and gastrointestinal discomfort) generally being mild to 
moderate (and rarely leading to medication discontinuation). 
Close observation (especially during the ﬁ  rst 4 weeks of 
treatment) may be necessary to watch for the development 
of a skin rash. 
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